Considerations and perspectives on the practice of incurred sample reanalysis assessment for chiral drugs

Documenti analoghi

• Insights Influencing the Selection of Stable Isotopically Labeled Internal Standards (SIL‐ISs) for LC–MS/MS Quantitative Assays
  di: Nuggehally R. Srinivas, et al.
  Pubblicazione: (2025)
• Incurred sample reanalysis (ISR) in clinical bioanalysis—Is it really a one‐size‐fits‐all solution?
  di: Nuggehally R. Srinivas, et al.
  Pubblicazione: (2024)
• An LC–MS/MS Method for the Quantitation of Metabolites M9, M12, and M20 of Bexicaserin in Human Cerebrospinal Fluid
  di: Raja Reddy Kallem, et al.
  Pubblicazione: (2026)
• A Highly Sensitive Triple Quad LC–MS/MS Method Development and Validation for the Determination of Bexicaserin (LP352) in Human Plasma and Urine Matrices
  di: Raja Reddy Kallem, et al.
  Pubblicazione: (2025)
• Development and Validation of an LC–MS/MS Method for the Quantitative Estimation of Bexicaserin in Human Cerebrospinal Fluid
  di: Raja Reddy Kallem, et al.
  Pubblicazione: (2026)